The ongoing, signal-seeking phase II portion of the phase II/III study evaluating Granite, a personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer, produced positive preliminary data.
The Community Health Center of the New River Valley and the University of Virginia Cancer Center partnered to boost southwest Virginia’s colorectal cancer screening rate by mailing at-home test kits to patients.
A study led by USC Norris Comprehensive Cancer Center, part of the Keck School of Medicine of USC, analyzed data on red and processed meat intake from 29,842 people with colorectal cancer and 39,635 people without cancer.
Developers of an investigational multi-target screening test for colorectal cancer and its precursors are aiming to replace the widely used conventional fecal immunochemical test.
A recent survey commissioned by the OSUCCC—James found that, while most U.S. adults identify family history (DNA-based risk passed down through families) as a risk factor for colorectal cancer, other factors such as alcohol use, lack of physical activity, and an American diet that is high in fat and processed foods were less known.
OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences earned a three-year accreditation from the National Accreditation Program for Rectal Cancer, making it the only accredited program in Oklahoma and one of only three other accredited programs within a 500-mile radius to receive the accreditation from the quality program of the American College of Surgeons.
Mainz Biomed N.V. and Praxisdienst formed a distribution partnership focused on the accessibility of Mainz Biomed’s flagship product, ColoAlert.
The NEST-1 study, which is evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer, both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High CRC (MSI-High), has demonstrated positive results.
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
Tempus has added a novel MRD assay, xM, to its testing solutions.
